Literature DB >> 17645871

Plasma PCSK9 levels correlate with cholesterol in men but not in women.

Janice Mayne1, Angela Raymond, Anna Chaplin, Marion Cousins, Nadine Kaefer, Charles Gyamera-Acheampong, Nabil G Seidah, Majambu Mbikay, Michel Chrétien, Teik Chye Ooi.   

Abstract

Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that negatively regulates low density lipoprotein receptor (LDLR) levels. Several single nucleotide polymorphisms (SNPs) in PCSK9 have been linked to autosomal dominant hypercholesterolemia (ADH). Conversely, hypocholesterolemia associates with both 'loss of function' nonsense and missense SNPs in PCSK9. We examined the association of plasma PCSK9 with lipoprotein parameters in 182 normolipidemics. For men (n=98) plasma PCSK9 averaged 6.08+/-1.96 microg/ml and Spearman analysis revealed significant correlation between it and total cholesterol (TC), LDLC, and TC/high density lipoprotein (HDLC) (r=0.276, 0.282, and 0.228, respectively). For women (n=84) plasma PCSK9 averaged 6.46+/-1.99 microg/ml having no correlation with TC, LDLC or TC/HDLC. The ratio of plasma PCSK9/LDLC increased in men carrying 'loss of function' PCSK9 variations. Our results suggest a gender difference in PCSK9 regulation and function with PCSK9 correlated to TC and LDLC in men but not women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645871     DOI: 10.1016/j.bbrc.2007.07.029

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people.

Authors:  Shelby Sullivan; Elisa Fabbrini; Jay D Horton; Kevin Korenblat; Bruce W Patterson; Samuel Klein
Journal:  Transl Res       Date:  2011-07-19       Impact factor: 7.012

2.  Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.

Authors:  Hagai Tavori; Ilaria Giunzioni; MacRae F Linton; Sergio Fazio
Journal:  Circ Res       Date:  2013-10-11       Impact factor: 17.367

Review 3.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

4.  Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.

Authors:  Elizabeth Theusch; Marisa W Medina; Jerome I Rotter; Ronald M Krauss
Journal:  Pharmacogenet Genomics       Date:  2014-10       Impact factor: 2.089

5.  Circulating PCSK9 is lowered acutely following surgery.

Authors:  Irena Druce; Hussein Abujrad; Seham Chaker; Hilary Meggison; Andrew Hill; Angela Raymond; Janice Mayne; Teik Chye Ooi
Journal:  J Clin Lab Anal       Date:  2017-11-17       Impact factor: 2.352

6.  Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels.

Authors:  Celia Rodríguez-Pérez; Vanu Ramkumar Ramprasath; Shuaihua Pu; Ali Sabra; Rosa Quirantes-Piné; Antonio Segura-Carretero; Peter J H Jones
Journal:  Lipids       Date:  2015-11-30       Impact factor: 1.880

7.  Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Authors:  Aldo Grefhorst; Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Lipid Res       Date:  2008-03-19       Impact factor: 5.922

8.  Genetic and metabolic determinants of plasma PCSK9 levels.

Authors:  Susan G Lakoski; Thomas A Lagace; Jonathan C Cohen; Jay D Horton; Helen H Hobbs
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

9.  Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

Authors:  Jean Davignon; Geneviève Dubuc
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

10.  A new method for measurement of total plasma PCSK9: clinical applications.

Authors:  Geneviève Dubuc; Michel Tremblay; Guillaume Paré; Hélène Jacques; Josée Hamelin; Suzanne Benjannet; Lucie Boulet; Jacques Genest; Lise Bernier; Nabil G Seidah; Jean Davignon
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.